Key result
Ivabradine is linked to a ~26% lower stroke-to-AF ratio vs placebo, suggesting increased AF diagnosis.
Why the study?
It was unclear whether ivabradine increases atrial fibrillation through a direct drug effect or augmented detection from greater heart-rate differentials prompting earlier clinical evaluation.
Does ivabradine directly cause atrial fibrillation or increase its detection, and how does this affect the incidence of ischemic cerebrovascular events?
Meta-Analysis (n=36,495)
Does ivabradine directly cause atrial fibrillation or increase its detection, and how does this affect the incidence of ischemic cerebrovascular events?
Effect estimate: RR 0.74 (95% CI 0.62-0.89)
p-value: p=<0.001
Ivabradine may facilitate increased detection of atrial fibrillation rather than directly causing it, potentially leading to earlier prophylaxis and a lower ratio of ischemic strokes to AF compared to placebo.
May prompt closer AF surveillance on ivabradine to enable timely anticoagulation; extends meta-analytic evidence that the drug does not raise ischemic stroke risk.
Background: Previous RCTs and meta-analyses observed an increased occurrence of atrial fibrillation (AF) associated with ivabradine use. Nonetheless, these studies were not focused on AF diagnosis, and it remains unclear whether this observed increase is due to a direct effect of ivabradine or just an augmented AF detection. The latter mechanism could arise from a greater heart-rate differential between sinus rhythm and AF under ivabradine, potentially intensifying symptoms and prompting earlier clinical evaluation. If this hypothesis is true, an earlier diagnosis of AF, and subsequent earlier prophylaxis with anticoagulants, may result in a reduced incidence of ischemic cerebrovascular events. Methods: We conducted a meta-analysis of the existing literature (calculating the ratio between ischemic cerebrovascular events and AF) combined with a disproportionality analysis of individual case safety reports of suspected adverse drug reactions. In the disproportionality analysis, we also included beta-blockers as a comparator group, given their dromotropic effect. Results: From 555 studies screened in the meta-analysis, only three were considered eligible. The ratio between ischemic cerebrovascular events and AF with ivabradine was lower than with placebo (RR 0.74, 95% CI 0.62-0.89; p < 0.001). In the FAERS, AF was disproportionally reported with both ivabradine and beta-blockers (Information Component 0.84, 95% CI 0.43-1.14 and Information Component 0.53, 95% CI 0.44-0.60), while ischemic cerebrovascular events only with beta-blockers (Information Component 0.25, 95% CI 0.18-0.31). Conclusion: Our findings raise the hypothesis that ivabradine facilitates an increased diagnosis rather than playing a direct role in causing AF. Prospective studies with continuous ECG monitoring and standardized endpoints are needed to clarify the temporal and mechanistic relationship between ivabradine, AF recognition, and cerebrovascular risk.
No takes yet. Share an insight, caveat, or question.
Spadotto et al. (2025) conducted a meta-analysis in Heart failure and stable coronary artery disease (n=36,495). Ivabradine vs. Placebo was evaluated on Ratio between ischemic cerebrovascular events and atrial fibrillation (RR 0.74, 95% CI 0.62-0.89, p=<0.001). Ivabradine was associated with a significantly lower ratio of ischemic cerebrovascular events to atrial fibrillation compared to placebo (RR 0.74), suggesting it facilitates increased AF diagnosis rather than directly causing AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: